secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056733
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled
--------------------------------------------------------------------------------

- YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).
- Net loss $4.9M vs. $13.6M YoY; Non-GAAP net income from operations $0.6M vs. loss of $8.6M.
- Operating expenses down ~20% YoY (ex-restructuring); restructuring on track for ~60% reduction by Q3 2026.
- All Hatch-Waxman YUPELRI litigation resolved; settlement with Mankind Pharma sets licensed launch date April 23, 2039.
- Cash $395M, no debt; Strategic Review Committee evaluating sale or other value-maximizing alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/0001104659-26-056733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/tm2613884d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer